Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

A method of prevention of symptomatic malaria in a human subject, comprising:

• a) administering to the human subject two or more primary doses of a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I), wherein at least the first primary dose is administered prior to potential exposure of the subject to at least one species of Plasmodium;
• and
• b) administering to the human subject one or more post-exposure dose(s) of a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I), within one week after the risk of continued exposure to at least one species of Plasmodium has substantially ended, wherein each said post-exposure dose comprises 75 mg to about 399 mg of the compound of Formula (I),
• wherein about 75 mg to about 399 mg of said compound of Formula (I) is administered in each of said two or more primary doses,
• wherein said primary doses are administered for about 1-21 days,
• wherein the at least one species of Plasmodium is P. vivax, P. falciparum, P. ovale, P. knowlsi, P. malariae, and/or P. berghei,
• wherein the human subject is malaria-naïve and Glucose-6-phosphate dehydrogenase (G6PD) normal, and
• wherein Formula (I) has the following structure,